Literature DB >> 25041874

Non-oncologic total femoral arthroplasty: retrospective review.

Derek F Amanatullah1, Robert T Trousdale1, Arlen D Hanssen1, David G Lewallen1, Michael J Taunton1.   

Abstract

Total femoral arthroplasty (TFA) is an option to amputation in the setting of excessive bones loss during revision total hip and knee arthroplasty. Twenty non-oncologic TFAs with a minimum of 2years follow-up were retrospectively reviewed. The average clinical follow-up was 73±49months. The incidence of new infection was 25% (5/20), while the overall infection rate was 35% (7/20). The incidence of primary hip instability was 10% (2/20), while the overall instability rate was 25% (5/20). Six patients (30%) required revision. The average pre-operative HHS was 30.2±13.1. The average post-operative HHS was 65.3±16.9. TFA is a viable alternative to amputation in non-oncologic patients with massive femoral bone deficiency. However, TFA performed poorly in the setting of infection and instability.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  TFA; above knee amputation; compromised bone stock; hip disarticulation; total femoral arthroplasty

Mesh:

Year:  2014        PMID: 25041874     DOI: 10.1016/j.arth.2014.05.012

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  10 in total

Review 1.  Current concepts in total femoral replacement.

Authors:  Deepak Ramanathan; Marcelo Bp Siqueira; Alison K Klika; Carlos A Higuera; Wael K Barsoum; Michael J Joyce
Journal:  World J Orthop       Date:  2015-12-18

2.  CORR Insights®: Length of Endoprosthetic Reconstruction in Revision Knee Arthroplasty Is Associated With Complications and Reoperations.

Authors:  Benjamin Kyle Potter
Journal:  Clin Orthop Relat Res       Date:  2016-05-18       Impact factor: 4.176

3.  Non-oncologic Total Femoral Arthroplasty: A Case Report.

Authors:  Max McCall; Andrew Corbett; Patricia Baumann
Journal:  Cureus       Date:  2022-04-25

4.  Length of Endoprosthetic Reconstruction in Revision Knee Arthroplasty Is Associated With Complications and Reoperations.

Authors:  Jeffrey J Barry; Zachary Thielen; David C Sing; Paul H Yi; Erik N Hansen; Michael Ries
Journal:  Clin Orthop Relat Res       Date:  2017-01       Impact factor: 4.176

5.  A Case Report of Dual Incision Technique for Total Femur Arthroplasty as a Salvage Procedure in Infected Non-Unions.

Authors:  Aniruddh Agrawal; Vinod Agrawal; Sandeepkumar Yadav; Shushil K Soni; Sawan Kumar Pawar
Journal:  J Orthop Case Rep       Date:  2017 Jul-Aug

6.  Interlocking reconstruction-mode stem-sideplates preserve at-risk hips with short residual proximal femora.

Authors:  Alexander B Christ; Tomohiro Fujiwara; Mohamed A Yakoub; John H Healey
Journal:  Bone Joint J       Date:  2021-02       Impact factor: 5.082

7.  Total femoral allograft with simultaneous revision total hip and knee arthroplasty: 18 year follow-up.

Authors:  Ryan N Harris; Trevor M Owen; Joseph T Moskal
Journal:  Arthroplast Today       Date:  2015-08-28

8.  Total femur arthroplasty for revision hip failure in osteogenesis imperfecta: limits of biology.

Authors:  Pablo Sanz-Ruiz; Manuel Villanueva-Martinez; Jose Antonio Calvo-Haro; Esther Carbó-Laso; Javier Vaquero-Martín
Journal:  Arthroplast Today       Date:  2017-03-06

9.  Short- to long-term follow-up of total femoral replacement in non-oncologic patients.

Authors:  Andreas Toepfer; Norbert Harrasser; Isabel Petzschner; Florian Pohlig; Ulrich Lenze; Ludger Gerdesmeyer; Dominik Pförringer; Marcel Toepfer; Marc Beirer; Moritz Crönlein; Ruediger von Eisenhart-Rothe; Heinz Mühlhofer
Journal:  BMC Musculoskelet Disord       Date:  2016-12-12       Impact factor: 2.362

10.  Is total femoral replacement for non-oncologic and oncologic indications a safe procedure in limb preservation surgery? A single center experience of 22 cases.

Authors:  Andreas Toepfer; Norbert Harrasser; Isabel Petzschner; Florian Pohlig; Ulrich Lenze; Ludger Gerdesmeyer; Ruediger von Eisenhart-Rothe; Heinrich Mühlhofer; Christian Suren
Journal:  Eur J Med Res       Date:  2018-01-16       Impact factor: 2.175

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.